Cantor Boosts Rocket Lab Target to Street-High $35

Rocket Lab (RKLB) received an analyst boost from Cantor Fitzgerald, raising its price target to a street-high of $35, citing the company's robust growth prospects, proven launch record of 66 successful launches, strategic advancements with the upcoming Neutron rocket, and recent acquisitions. The firm reaffirmed its Overweight rating on June 10, 2025, reflecting confidence in Rocket Lab's ability to leverage its $1.07 billion backlog and projected 31-33% revenue growth in FY2025; furthermore, Rocket Lab’s Electron vehicle continues to prove its value as a reliable and in-demand launch solution.

Analysis

Rocket Lab USA (RKLB) has garnered significant positive attention, underscored by Cantor Fitzgerald's recent upgrade of its price target to a street-high $35 on June 10, 2025, a 22% increase from their prior $29 target, while reaffirming an Overweight rating. This bullish stance, reflected in the strongly positive overall sentiment (0.8) and specific RKLB sentiment (0.9), is attributed to the company's robust growth prospects within the commercial space sector, a proven track record of 66 successful launches, strategic acquisitions bolstering its end-to-end space systems, and the anticipated debut of its Neutron rocket. The company's substantial $1.07 billion backlog and projected 31-33% revenue growth for FY2025 further support this optimism, even as the stock trades at a premium. Currently priced at $27.85 following a 5.41% increase, RKLB shares are consolidating above critical support near $25, with analysts suggesting further consolidation could precede a re-test of $30, particularly as anticipation builds for Neutron's maiden test flight scheduled for the second half of 2025. While the consensus analyst rating is a "Moderate Buy" with an average 12-month price target of $28.10, prominent analysts like Cantor Fitzgerald and Roth Capital see considerable upside to $35. Operationally, the Electron launch vehicle remains a key asset, securing new dedicated missions such as the "Symphony In The Stars" launch scheduled no earlier than June 20, 2025, and contributing to a busy manifest of over 20 missions planned for 2025 with a perfect success rate thus far in the year.

Key Decisions for Investors

• Investors should weigh the strong bullish outlook from specific analysts, supported by Rocket Lab's significant $1.07 billion backlog and projected 31-33% FY2025 revenue growth, against the broader 'Moderate Buy' consensus and the stock's current premium valuation.
• The maiden test flight of the Neutron rocket in the second half of 2025 represents a critical upcoming catalyst; its success could substantially de-risk future growth and potentially propel the stock beyond its current consolidation phase.
• Continuous monitoring of Electron's launch success rate and cadence, progress on Neutron's development, and new contract acquisitions is essential to validate the company's operational execution and its ability to achieve stated growth objectives.